|
|
|
|
|
||||||||||||
|
|
|
|
|
|
|
|
价值评估 |
盈利(现时/预测)
-9.18/-10.80
|
企业价值
7.35M
|
资产负债 |
每股账面净值
0.35
|
现金流量 |
现金流量率
--
|
损益表 |
收益
0
|
每股收益
0.03
|
同行比较
|
||||||||||||||||||||||||||||||||||||||||||||||||
|
报价延迟最少15分钟:2024/05/18 03:45 EDT
同行比较之报价最少15分钟延迟
业务概览
|
|||
Oragenics Inc is engaged in the research and development of nasal delivery pharmaceutical medications in neurology and fighting infectious diseases. The company's lead product ONP-002 is a fully synthetic, non-naturally occurring neurosteroid, is lipophilic, and can cross the blood-brain barrier to rapidly reduce swelling, oxidative stress and inflammation while restoring proper blood flow through gene amplification. |